Summary
Our team
Director Strategic Partnerships
VP Sales US
Field Application Specialist - AMERICAS SALES
Scientific Support Specialist
Lunch & Learn Roundtable – April 28: 1:10 pm – 1:50 pm EST
How to improve viral titers by optimizing your upstream process?
The current challenges in Gene therapy are increasing viral titer yields, and optimizing the industrial production process of AAVs that are becoming the leading viral vector used to develop Gene therapy. Optimizing key parameters of the upstream process, such as the critical transfection step, can really accelerate the time to market of gene therapies, and in sufficient amount to address diseases with larger patient population or that require bigger doses per patient. Come to discuss with the worldwide leader in transfection Polyplus-transfection during this exciting roundtable.
Roundtable hosted by Julien DEPOLLIER, Director Strategic Partnerships at Polyplus-transfection®.
Our solutions for both protein and virus production
FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.
PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.
FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).